Prashant Shah
About Prashant Shah
Prashant Shah is a Senior KCM Immuno-Oncology at Bristol-Myers Squibb with over two decades of experience in the pharmaceutical and healthcare industry.
Company
Prashant Shah currently works at Bristol-Myers Squibb, a global biopharmaceutical company, in London, United Kingdom. He has been with the company since 2014, serving in various capacities within their oncology and virology divisions. As of May 2019, he holds the position of Senior KCM Immuno-Oncology.
Title
Prashant Shah is the Senior KCM Immuno-Oncology at Bristol-Myers Squibb. His role involves managing key customer management (KCM) in the field of immuno-oncology, bringing his extensive experience to the forefront in handling accounts with both clinicians and financial stakeholders.
Education and Expertise
Prashant Shah earned his BSc (Hon) in Pharmacology from the University of East London, where he studied from 1991 to 1995. His education has laid the foundation for a prolific career in the pharmaceutical and healthcare industry, spanning over two decades. His expertise encompasses account management and sales within the health economy.
Professional Background
Prashant Shah's professional journey includes notable roles across several organizations. He started his career at IMS Health in 1997 as a Project Manager for Forecasting. He later moved to various other companies such as Chiesi Pharmaceuticals, sanofi-aventis, Abbott Healthcare, Decision Resources, and the Health Service Journal. Since 2014, he has been with Bristol-Myers Squibb, progressing from KCM roles in oncology and virology to his current senior position in immuno-oncology.
Industry Experience
With over twenty years of experience in the pharmaceutical and healthcare sector, Prashant Shah has a proven track record in managing accounts effectively among a diverse range of customers within the health economy. His tenure includes high-responsibility positions that involve significant sales and account management duties, aimed at both clinical and financial stakeholders.